Phase IIb data scratch the itch for Creabilis

Creabilis has reported positive Phase IIb data from with its lead anti-itch product CT327, a novel topical TrkA kinase inhibitor, in psoriasis patients, although not all study endpoints were met.

Creabilis has reported positive Phase IIb data from with its lead anti-itch product CT327, a novel topical TrkA kinase inhibitor, in psoriasis patients, although not all study endpoints were met.

Creabilis, a Luxembourg-based firm focused solely on itching (chronic pruritus), said patients receiving CT327 showed a significant reduction in pruritus,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Dermatological

More from Therapeutic Category